Posted by Michael Wonder on 29 Aug 2024
European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus vaccine for adults aged 50-59 at increased risk
29 August 2024 - This follows approval in US, with other countries anticipated, including Japan later this year.
GSK today announced that the European Commission has authorised Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults aged 50-59 who are at increased risk.
